Kindstar Globalgene Technology (HKSE:09960) COGS-to-Revenue : 0.53 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Kindstar Globalgene Technology COGS-to-Revenue?

Kindstar Globalgene Technology's Cost of Goods Sold for the six months ended in Dec. 2024 was HK$256.7 Mil. Its Revenue for the six months ended in Dec. 2024 was HK$485.0 Mil.

Kindstar Globalgene Technology's COGS to Revenue for the six months ended in Dec. 2024 was 0.53.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Kindstar Globalgene Technology's Gross Margin % for the six months ended in Dec. 2024 was 47.06%.

Kindstar Globalgene Technology COGS-to-Revenue Historical Data

The historical data trend for Kindstar Globalgene Technology's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kindstar Globalgene Technology COGS-to-Revenue Chart

Kindstar Globalgene Technology Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.48

0.57

0.53

Kindstar Globalgene Technology Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial							0.58	0.50	0.56	0.52	0.53

Kindstar Globalgene Technology COGS-to-Revenue Calculation

Kindstar Globalgene Technology's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	521.029	/	990.338
	=	0.53

Kindstar Globalgene Technology's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	256.733	/	484.972
	=	0.53

Kindstar Globalgene Technology (HKSE:09960) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Kindstar Globalgene Technology's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	256.733 / 484.972
	=	47.06 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Kindstar Globalgene Technology COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kindstar Globalgene Technology's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Kindstar Globalgene Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Kindstar Globalgene Technology Inc (HKSE:09960) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN

Website

https://www.kindstar.com.cn

Kindstar Globalgene Technology Inc is principally engaged in the provision of clinical testing services in China. It organizes the business into the following segments; hematology testing, genetic disease and rare disease testing, infectious disease testing, oncology testing, neurology testing, maternity-related testing, COVID-19-related testing, routine testing, scientific research services and CRO, and other segments provide testing services for R&D projects and others and miscellaneous services.

Executives

Mialkos Tomasz Jakub	2101 Beneficial owner
Orbimed Asia Partners Iv, L.p.	2101 Beneficial owner
Orbimed Asia Gp Iv, L.p.	2201 Interest of corporation controlled by you
Orbimed Advisors Iv Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Ck Lab Tech Investment Limited	2101 Beneficial owner
Huang Bo
Jackson Hole Trust Company
Huang Shiang	2101 Beneficial owner
Ningbo Meishan Bonded Port Zone Ruifu Bojian Investment Management Co., Ltd.
Huang Zuie-chin	2101 Beneficial owner
Tu Zanbing

Kindstar Globalgene Technology Headlines

No Headlines